SOURCE: NuPathe Inc.

NuPathe Inc.

October 08, 2012 07:00 ET

NuPathe to Present at the Safeguard Scientifics Investor Day 2012

CONSHOHOCKEN, PA--(Marketwire - Oct 8, 2012) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Armando Anido, chief executive officer, will present a company overview at the Safeguard Scientifics Investor Day 2012 at The Yale Club of New York City on Tuesday, October 9, 2012 at approximately 10:30 am EDT.

To listen to the live call, please dial 877-317-6789 (domestic) or +1-412-317-6789 (international), approximately 10 minutes before the presentation time, or go to for the live webcast. A replay of the call and webcast will be available through November 9, 2012 at 9:00 am ET. Investors may listen to the replay of the call by dialing 877-344-7529 (domestic) or +1-412-317-0088 (international), with the replay access code of 10019309.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website through November 9, 2012 at 9:00 am ET.

If you are interested in attending or for additional information, please visit Safeguard's microsite at

About NuPathe
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for its product candidates in the U.S. and territories throughout the world.

For more information about NuPathe, please visit our website and our blog at You can also follow us on StockTwits (, Twitter (, SlideShare ( and LinkedIn (

Cautionary Note Regarding Forward-Looking Statements
NuPathe's presentation at the Safeguard Scientifics Investor Day 2012 will contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: NuPathe's ability to satisfy the closing conditions and complete its recently announced financing; the sufficiency of the proceeds to be received upon closing of the financing, together with recent cost containment measures, to fund operations into the fourth quarter of 2013; partnering and commercialization plans for NP101; the timing and prospects for FDA approval of NP101; the potential benefits of, and commercial opportunity for, NP101; and other statements relating to NuPathe's future operations, performance, financial condition, beliefs, plans or objectives.

Forward-looking statements are based upon NuPathe's current expectations, plans and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and events to differ materially and adversely from those indicated by such statements including, among others: NuPathe's ability to satisfy the closing conditions and complete the financing; NuPathe's ability to continue operations until the closing of the financing; FDA approval of NP101; the extent to which the FDA may request or require additional information, studies or redesign of NP101; varying interpretation of study and market data; and the other factors discussed in NuPathe's Annual Report on Form 10-K for the year ended December 31, 2011, under the caption "Risk Factors" and elsewhere in such report, which is available on NuPathe's website at in the "Investor Relations -- SEC Filings" section. While NuPathe may update certain forward-looking statements and Risk Factors from time to time, NuPathe specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.

Contact Information

  • Contact Information:

    John Woolford
    Westwicke Partners, LLC
    (443) 213-0506

    Keith A. Goldan
    Vice President & Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130